Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ingrid Paredes

Obstetrics & Gynecology Miami, FL Medical Doctor

NPI 1316307374 CMS profile 1812324

7800 Sw 87Th Ave, Miami, FL 33173

Open in the dashboard

General payments

$65,486

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ingrid Paredes of Miami, FL is reported in the CMS Open Payments database as having received $65,486 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,282 48
2024 General $17,836 58
2023 General $18,111 34
2022 General $12,765 30
2021 General $546 20
2020 General $210 6
2019 General $737 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ingrid Paredes
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Ingrid Paredes were reported at $15,282. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Ingrid Paredes Obstetrics & Gynecology median Middle half National median
2019 $737 $172 $62–$391 $163
2020 $210 $94 $36–$222 $114
2021 $546 $136 $42–$369 $132
2022 $12,765 $160 $50–$433 $149
2023 $18,111 $169 $56–$423 $160
2024 $17,836 $152 $50–$371 $164
2025 $15,282 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $33,660 55 payments
  2. Exeltis, USA Inc. $17,673 14 payments
  3. Intuitive Surgical, Inc. $9,792 8 payments
  4. CONMED Corporation $660 10 payments
  5. AbbVie, Inc. $497 24 payments
  6. Mayne Pharma Inc. $465 16 payments
  7. Astellas Pharma US Inc $335 12 payments
  8. Davol Inc. $301 3 payments
  9. Novo Nordisk Inc $299 5 payments
  10. Hologic, LLC $263 7 payments
  11. Other $1,541 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,251 7 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,560 6 payments
  3. Education $9,064 6 payments
  4. Food and Beverage $5,895 167 payments
  5. Travel and Lodging $2,716 18 payments
Products named General payments · program years 2019–2025
  1. Zurzuvae $28,640 50 payments
  2. SLYND Oral contraceptive $16,848 3 payments
  3. DAVINCI XI $9,000 3 payments
  4. Da Vinci Surgical System $792 5 payments
  5. AIRSEAL $660 10 payments
  6. SLYND Oral contraceptive $634 2 payments
  7. LO LOESTRIN FE $344 16 payments
  8. Veozah $314 11 payments
  9. Phasix Mesh $301 3 payments
  10. Wegovy $299 5 payments
  11. Other $2,447 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Obstetrics & Gynecology: 65

Drug cost

$321

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Progesterone Progesterone, Micronized Brand 16 $321

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$3,152

Medicare's payments for the services billed

Medicare patients

16

Average age 68

Services billed

38

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Atrial fibrillation 0%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $250
$250 — —
Wegovy
  • Novo Nordisk Inc $141
$141 — —
SLYND
  • Exeltis, USA Inc. $95
$95 — —
ABRYSVO
  • PFIZER INC. $25
$25 — —
ZEPBOUND
  • Lilly USA, LLC $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record